Physician profile
Kenneth Burnham
NPI 1164462321
$445,713.38
in general payments reported to CMS, 2019-2025
33 companies · $124K in 2025
The $124K reported for 2025 was more than what 99% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77K · 2020: $31K · 2021: $40K · 2022: $33K · 2023: $62K · 2024: $79K · 2025: $124K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $190K · Honoraria: $44K · Travel and Lodging: $14K · Food and Beverage: $13K · Consulting Fee: $3,925 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $190,324.50 |
| Honoraria | $44,100.00 |
| Travel and Lodging | $14,080.46 |
| Food and Beverage | $12,656.98 |
| Consulting Fee | $3,925.00 |
| Education | $129.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $108,479.94 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $68,182.02 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62,269.73 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $60,968.49 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Pfizer INC. | $60,297.30 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $48,820.69 | 2023-2025 | Inpefa |
| Lilly USA, LLC | $10,587.63 | 2022-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $7,900.92 | 2019-2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $5,451.67 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $5,225.52 | 2020-2025 | Uptravi, Opsumit, Opsynvi |
| Cvrx, INC. | $4,395.51 | 2023-2025 | Barostim Neo System |
| Abbott Laboratories | $544.04 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Scpharmaceuticals INC. | $502.79 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $351.72 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $291.62 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $229.00 | 2019-2025 | Repatha, Repatha |
| United Therapeutics Corporation | $224.59 | 2019-2025 | Tyvaso |
| Atricure, INC. | $180.91 | 2024 | |
| Abiomed | $175.37 | 2021-2024 | Impella |
| Esperion Therapeutics, INC. | $124.99 | 2021 | |
| Sensible Medical Innovations INC | $98.46 | 2019-2023 | Reds System |
| Bridgebio Pharma, INC. | $65.81 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, Ltd. | $60.15 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $59.18 | 2024 | Arcalyst |
| Lantheus Medical Imaging, INC. | $48.69 | 2023-2025 | Definity |
| Novo Nordisk INC | $33.92 | 2022 | |
| Vivaquant INC, Dba Rhythm Express | $29.28 | 2024 | Rhythm Express |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.44 | 2024 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $22.50 | 2021 | |
| Medtronic Vascular, INC. | $21.17 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.05 | 2023 | Edarbyclor |
| Liquidia Technologies, INC. | $14.70 | 2025 | Yutrepia |
| Akcea Therapeutics, INC. | $13.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Burnham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.